HUE058746T2 - Antiproliferációs vegyületek és felhasználásuk - Google Patents
Antiproliferációs vegyületek és felhasználásukInfo
- Publication number
- HUE058746T2 HUE058746T2 HUE19726792A HUE19726792A HUE058746T2 HU E058746 T2 HUE058746 T2 HU E058746T2 HU E19726792 A HUE19726792 A HU E19726792A HU E19726792 A HUE19726792 A HU E19726792A HU E058746 T2 HUE058746 T2 HU E058746T2
- Authority
- HU
- Hungary
- Prior art keywords
- antiproliferation
- compounds
- antiproliferation compounds
- Prior art date
Links
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862661719P | 2018-04-24 | 2018-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE058746T2 true HUE058746T2 (hu) | 2022-09-28 |
Family
ID=66655429
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE19726792A HUE058746T2 (hu) | 2018-04-24 | 2019-04-23 | Antiproliferációs vegyületek és felhasználásuk |
| HUE22161962A HUE067936T2 (hu) | 2018-04-24 | 2019-04-23 | Proliferáció-gátló vegyületek és alkalmazásuk |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE22161962A HUE067936T2 (hu) | 2018-04-24 | 2019-04-23 | Proliferáció-gátló vegyületek és alkalmazásuk |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10815225B2 (https=) |
| EP (2) | EP3784666B1 (https=) |
| JP (2) | JP7304892B2 (https=) |
| KR (1) | KR102813581B1 (https=) |
| CN (1) | CN112236428B (https=) |
| AR (1) | AR114496A1 (https=) |
| AU (1) | AU2019261308B2 (https=) |
| BR (1) | BR112020020940A2 (https=) |
| CA (1) | CA3098335A1 (https=) |
| CY (1) | CY1125433T1 (https=) |
| DK (2) | DK4043460T3 (https=) |
| ES (2) | ES2987356T3 (https=) |
| FI (1) | FI4043460T3 (https=) |
| HR (2) | HRP20241163T1 (https=) |
| HU (2) | HUE058746T2 (https=) |
| IL (2) | IL278142B2 (https=) |
| LT (1) | LT3784666T (https=) |
| MX (1) | MX2020011089A (https=) |
| PL (2) | PL3784666T3 (https=) |
| PT (2) | PT3784666T (https=) |
| RS (1) | RS63281B1 (https=) |
| SG (1) | SG11202009500QA (https=) |
| SI (1) | SI3784666T1 (https=) |
| SM (1) | SMT202200308T1 (https=) |
| TW (1) | TWI813673B (https=) |
| WO (1) | WO2019209759A1 (https=) |
| ZA (1) | ZA202006071B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20241163T1 (hr) | 2018-04-24 | 2024-11-22 | Merck Patent Gmbh | Antiproliferacijski spojevi i njihova uporaba |
| WO2020010451A1 (en) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| WO2020236834A1 (en) * | 2019-05-20 | 2020-11-26 | Seshadri Raju | Modified z stents for iliac vein stenting |
| CN118496197A (zh) | 2019-12-20 | 2024-08-16 | 拜耳公司 | 取代的噻吩甲酰胺、噻吩甲酸及其衍生物 |
| WO2024073502A1 (en) * | 2022-09-28 | 2024-04-04 | Accutar Biotechnology Inc. | Heterocyclic compounds as e3 ligase inhibitors |
| TW202547516A (zh) * | 2024-04-26 | 2025-12-16 | 大陸商正大天晴藥業集團股份有限公司 | 稠合雙環化合物及其用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| DE19840028A1 (de) | 1998-09-02 | 2000-03-09 | Max Planck Gesellschaft | Nucleinsäuremoleküle codierend Enzyme, die Fructosyltransferaseaktivität besitzen, und deren Verwendung |
| DE60037345T2 (de) | 1999-12-10 | 2008-11-13 | Pfizer Products Inc., Groton | Pyrrolo(2,3-d)pyrimidin-Verbindungen |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| DE60217322T2 (de) | 2001-04-27 | 2007-10-04 | Zenyaku Kogyo K.K. | Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| PT1536827E (pt) | 2002-08-14 | 2009-03-20 | Silence Therapeutics Ag | Utilização de proteína cinase n beta |
| AU2004228668B2 (en) | 2003-04-03 | 2011-10-27 | Park Funding, Llc | PI-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| EP1692153A4 (en) | 2003-07-03 | 2007-03-21 | Univ Pennsylvania | INHIBITION OF EXPRESSION OF SYK-KINASE |
| WO2005113556A1 (en) | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| US7989622B2 (en) | 2005-10-07 | 2011-08-02 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2007129161A2 (en) | 2006-04-26 | 2007-11-15 | F. Hoffmann-La Roche Ag | Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| KR101566840B1 (ko) | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| HUE029767T2 (en) | 2008-03-11 | 2017-04-28 | Incyte Holdings Corp | JAK inhibitor azetidine and cyclobutane derivatives |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| DE102008031517A1 (de) * | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
| CA2729045A1 (en) | 2008-07-31 | 2010-02-04 | Philippe Bergeron | Pyrimidine compounds, compositions and methods of use |
| AR076014A1 (es) | 2009-04-02 | 2011-05-11 | Sanofi Aventis | Derivados de 3- (1,4) oxazepan -4-pirimidona |
| BR112012012905A2 (pt) * | 2009-12-04 | 2017-03-01 | Hoffmann La Roche | derivados de difenil azepina como inibidores da reabsorção de monoamina |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP3256132A1 (en) * | 2015-02-13 | 2017-12-20 | Merck Patent GmbH | Pyrimidine derivatives for use in the treatment of cancer |
| HRP20241163T1 (hr) | 2018-04-24 | 2024-11-22 | Merck Patent Gmbh | Antiproliferacijski spojevi i njihova uporaba |
-
2019
- 2019-04-23 HR HRP20241163TT patent/HRP20241163T1/hr unknown
- 2019-04-23 DK DK22161962.0T patent/DK4043460T3/da active
- 2019-04-23 ES ES22161962T patent/ES2987356T3/es active Active
- 2019-04-23 HR HRP20220710TT patent/HRP20220710T1/hr unknown
- 2019-04-23 BR BR112020020940-6A patent/BR112020020940A2/pt active Search and Examination
- 2019-04-23 KR KR1020207033873A patent/KR102813581B1/ko active Active
- 2019-04-23 SM SM20220308T patent/SMT202200308T1/it unknown
- 2019-04-23 AR ARP190101062A patent/AR114496A1/es unknown
- 2019-04-23 PT PT197267925T patent/PT3784666T/pt unknown
- 2019-04-23 SI SI201930251T patent/SI3784666T1/sl unknown
- 2019-04-23 US US16/391,419 patent/US10815225B2/en active Active
- 2019-04-23 PT PT221619620T patent/PT4043460T/pt unknown
- 2019-04-23 LT LTEPPCT/US2019/028607T patent/LT3784666T/lt unknown
- 2019-04-23 IL IL278142A patent/IL278142B2/en unknown
- 2019-04-23 MX MX2020011089A patent/MX2020011089A/es unknown
- 2019-04-23 WO PCT/US2019/028607 patent/WO2019209759A1/en not_active Ceased
- 2019-04-23 AU AU2019261308A patent/AU2019261308B2/en active Active
- 2019-04-23 JP JP2020559394A patent/JP7304892B2/ja active Active
- 2019-04-23 TW TW108114146A patent/TWI813673B/zh active
- 2019-04-23 IL IL301501A patent/IL301501B2/en unknown
- 2019-04-23 FI FIEP22161962.0T patent/FI4043460T3/fi active
- 2019-04-23 HU HUE19726792A patent/HUE058746T2/hu unknown
- 2019-04-23 CA CA3098335A patent/CA3098335A1/en active Pending
- 2019-04-23 ES ES19726792T patent/ES2919572T3/es active Active
- 2019-04-23 EP EP19726792.5A patent/EP3784666B1/en active Active
- 2019-04-23 SG SG11202009500QA patent/SG11202009500QA/en unknown
- 2019-04-23 PL PL19726792.5T patent/PL3784666T3/pl unknown
- 2019-04-23 CN CN201980036896.XA patent/CN112236428B/zh active Active
- 2019-04-23 EP EP22161962.0A patent/EP4043460B1/en active Active
- 2019-04-23 DK DK19726792.5T patent/DK3784666T3/da active
- 2019-04-23 RS RS20220537A patent/RS63281B1/sr unknown
- 2019-04-23 HU HUE22161962A patent/HUE067936T2/hu unknown
- 2019-04-23 PL PL22161962.0T patent/PL4043460T3/pl unknown
-
2020
- 2020-08-27 US US17/004,109 patent/US11440907B1/en active Active
- 2020-09-30 ZA ZA2020/06071A patent/ZA202006071B/en unknown
-
2022
- 2022-06-10 CY CY20221100409T patent/CY1125433T1/el unknown
- 2022-09-07 US US17/930,352 patent/US12195453B2/en active Active
-
2023
- 2023-06-05 JP JP2023092450A patent/JP2023101824A/ja active Pending
-
2024
- 2024-11-08 US US18/941,447 patent/US20250188070A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285177A (en) | compounds and their use | |
| IL273236A (en) | Pyrazolopyrimidine compounds and their uses | |
| IL294052B2 (en) | Fluoroalkyl oxadiazoles and their uses | |
| IL277502A (en) | Compounds and uses for them | |
| IL286497A (en) | compounds and their use | |
| GB201803568D0 (en) | Novel compounds and uses | |
| IL278142A (en) | Antiproliferative compounds and their uses | |
| IL276753A (en) | Epibrotic compounds, their devices and uses | |
| IL272055A (en) | 8,1-naphthyridinone compounds and their uses | |
| IL291499A (en) | Azaquinoline compounds and their uses | |
| SG11202108079RA (en) | Compounds and uses thereof | |
| ZA202105752B (en) | Haloallylamine compounds and application thereof | |
| GB201801102D0 (en) | New compounds and uses | |
| IL284764A (en) | compounds and their uses | |
| IL279483A (en) | Cyanotriazole compounds and their uses | |
| IL287503A (en) | Thio-semicarbazide compounds and their use | |
| IL280644A (en) | Magnesium serine compound and its use | |
| GB201812078D0 (en) | Novel compounds and their uses | |
| ZA202201239B (en) | Aminothiolester compounds and uses thereof | |
| GB201804098D0 (en) | Novel compounds and therapeutic uses thereof | |
| IL280369A (en) | Myokines and their uses | |
| GB201806349D0 (en) | New compounds and uses | |
| IL283540A (en) | Dock1 inhibitory compound and use thereof | |
| GB201810667D0 (en) | New compounds and uses | |
| HK40043702A (en) | Cyanotriazole compounds and uses thereof |